Journal of Neurology最新文献

{"title":"A multi-domain lifestyle intervention in multiple sclerosis: a longitudinal observational study.","authors":"Ilse M Nauta, Keeva N M Loughlin, Arianne S Gravesteijn, Jade van Wegen, Rosa P Hofman, Nathalie Wilmsen, Emma Coles, Zoé L E van Kempen, Joep Killestein, Bob W van Oosten, Eva M M Strijbis, Bernard M J Uitdehaag, Brigit A de Jong","doi":"10.1007/s00415-025-13196-9","DOIUrl":"10.1007/s00415-025-13196-9","url":null,"abstract":"<p><strong>Objective: </strong>To examine the effects of a multi-domain lifestyle intervention that advocated a Mediterranean style diet, and concurrently targeted physical activity, stress and sleep, on multiple sclerosis.</p><p><strong>Methods: </strong>A longitudinal observational study investigating the effect of a multi-domain lifestyle intervention (i.e., diet, exercise, stress, and sleep management) at four timepoints: start run-in, start and stop 3-month intensive interval, and 3-month follow-up. The primary outcome (i.e., impact of multiple sclerosis on daily functioning) and secondary outcomes (i.e., quality of life, general health, multiple sclerosis-specific symptoms, and lifestyle factors) were analyzed using mixed models. Analyses were repeated among subgroups based on program compliance, body mass index, education level, and multiple sclerosis-subtype.</p><p><strong>Results: </strong>Out of 668 participants, 579 were included (age 46.2 ± 10.5 years, 84.5% women, and 71% relapsing-remitting multiple sclerosis). The impact of multiple sclerosis on physical functioning remained stable during the run-in period, but reduced significantly from baseline to both post-intervention (β = -2.50 [-3.40, -1.60]) and to 3-month follow-up (β = -2.00 [-2.93, -1.07]). The impact of multiple sclerosis on mental functioning decreased significantly across all time periods (run-in β = 1.86 [0.78, 2.94], post-intervention β = -3.48 [-4.58, -2.39], and 3-month follow-up β = -2.44 [-3.56, 1.31]). Effect size was greatest among participants with higher compliance, lower education, and obesity.</p><p><strong>Interpretation: </strong>The lifestyle program was associated with reduced impact of multiple sclerosis on daily functioning, multiple sclerosis-related symptoms, mental quality of life, and general health determinants. Future randomized trials are needed to establish causal effects of lifestyle adjustments on multiple sclerosis.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"476"},"PeriodicalIF":4.8,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12187891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autosomal recessive Bethlem myopathy: a 30-year journey.","authors":"Annamaria Gallone, Giorgia Riolo, Alessandra Ruggieri, Eliana Iannibelli, Franco Salerno, Lucia Nicolini De Gaetano, Alessandra Carnazzi, Lorenzo Maggi, Sara Gibertini","doi":"10.1007/s00415-025-13214-w","DOIUrl":"10.1007/s00415-025-13214-w","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"473"},"PeriodicalIF":4.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12185608/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of different durations of dual antiplatelet therapy in acute minor non-cardioembolic stroke: a systematic review and network meta-analysis.","authors":"Wuchaonan Liu, Shengping Luo, Ruiyu Huang, Yujia Li, Dingxiang Li, Yihui Deng","doi":"10.1007/s00415-025-13210-0","DOIUrl":"10.1007/s00415-025-13210-0","url":null,"abstract":"<p><strong>Background: </strong>International guidelines recommend short-course dual antiplatelet therapy (DAPT) for secondary prevention in patients with acute minor stroke. However, the optimal duration of such therapy remains unclear. This review aims to evaluate and compare the efficacy and safety of different DAPT durations in the secondary prevention of acute minor ischemic stroke.</p><p><strong>Methods: </strong>The present study systematically searched PubMed, Embase (via Ovid), Cochrane Library, Web of Science, China National Knowledge Infrastructure (CNKI), and ClinicalTrials.gov to identify relevant randomized-controlled trials. The primary outcome was the incidence of all recurrent strokes. Data synthesis was performed through network meta-analysis and paired meta-analysis methodologies.</p><p><strong>Results: </strong>A total of 7 studies with 34,646 participants were included. Compared with aspirin alone, each course of DAPT reduced the risk of recurrent stroke but increased the risk of bleeding: aspirin-clopidogrel 21 day DAPT (OR 0.75,95% CI 0.66-0.85)/(OR 1.48, 95% CI 1.16-1.89); aspirin-ticagrelor 30 day DAPT (OR 0.81,95% CI 0.70-0.95)/(OR 3.98,95% CI 1.74-9.10); aspirin-clopidogrel 90 day DAPT (OR 0.75,95% CI 0.60-0.93)/(OR 2.02, 95% CI 1.42-2.88). Compared with aspirin-clopidogrel 21 day DAPT, aspirin-ticagrelor 21 day DAPT was more efficacious with an increased risk of bleeding (OR 0.78,95% CI 0.65-0.92)/(OR 1.86, 95% CI 1.39-2.49). Network meta-analysis showed that aspirin-clopidogrel 21 day DAPT had the best risk-benefit profile, followed by aspirin-ticagrelor 21 day DAPT and aspirin-clopidogrel 90 day DAPT, with aspirin alone being the least effective.</p><p><strong>Conclusions: </strong>The risk-benefit profile of 21 day DAPT with aspirin-clopidogrel was superior to that of other short-course DAPTs.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"474"},"PeriodicalIF":4.8,"publicationDate":"2025-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144475684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KCNT1 gene variant-associated epilepsy: genetic insights, functional mechanisms, and emerging therapies.","authors":"Ya-Ze Duan, Tong-Tong Yao, Yi-Ting Shao, Li-Ming Liu, Hui Zhou, Yong Cheng","doi":"10.1007/s00415-025-13207-9","DOIUrl":"10.1007/s00415-025-13207-9","url":null,"abstract":"<p><p>KCNT1 gene variant-associated epilepsy is a rare genetic disorder with a wide clinical spectrum, ranging from mild symptoms to severe, early onset epileptic encephalopathies. It is commonly characterized by focal seizures, drug resistance, and neurodevelopmental impairments. This review summarizes recent advances in understanding the disorder's molecular mechanisms, clinical features, experimental models, and emerging therapeutic approaches. KCNT1 mutations disrupt potassium channel function, altering neuronal excitability and impairing network stability. Experimental models-including mice, Drosophila, and patient-derived cells-have provided critical insights into disease mechanisms and potential interventions. In particular, KCNT1 knock-in mouse and cellular models have clarified how specific variants drive disease progression and therapeutic response. Promising strategies under investigation include gene therapy, small-molecule modulators, and ketogenic dietary (KD) interventions, all aimed at restoring neuronal balance. These developments highlight the central role of potassium channel dysfunction in the pathophysiology of KCNT1-related epilepsy. Nevertheless, current models do not fully recapitulate the human condition, underscoring the need for continued research. This review aims to support ongoing efforts to refine precision therapies and improve outcomes for patients affected by this complex disorder.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"472"},"PeriodicalIF":4.8,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, timing and characteristics of delirium preceding dementia with Lewy bodies: a retrospective case series.","authors":"Janice Taylor, Chaminda Gunawardana, Simon J G Lewis, Elie Matar","doi":"10.1007/s00415-025-13193-y","DOIUrl":"10.1007/s00415-025-13193-y","url":null,"abstract":"<p><strong>Background: </strong>Consensus diagnostic criteria for delirium-onset dementia with Lewy bodies are lacking. This retrospective study aimed to identify delirium occurring in the prodrome of dementia with Lewy bodies (DLB), exploring delirium-onset DLB as an entity and its natural history.</p><p><strong>Methods: </strong>Thirty-four participants with an established diagnosis of probable DLB from an outpatient neurology clinic in Sydney underwent a structured telephone interview to identify episodes of delirium. The timing, precipitants, and phenomenology of each episode were documented. Core and supportive features from the proposed diagnostic criteria for DLB were evaluated.</p><p><strong>Results: </strong>26% of the participants experienced delirium prior to diagnosis of DLB, with one participant experiencing multiple episodes in the 24 months before diagnosis. Of these cases, 66% demonstrated some core and supportive features of DLB at the time of their delirium. In addition to expected triggers (e.g. surgery), international (long-haul) air flight was identified as one of the commonest precipitants for delirium in this group. Those DLB cases who fulfilled the proposed research criteria for a delirium-onset prodrome experienced a shorter time from symptom onset to dementia than those DLB patients with no history of pre-diagnosis delirium (26 vs 40 months).</p><p><strong>Conclusions: </strong>These findings support delirium as a marker of prodromal DLB and suggest delirium-onset cases exhibit a more rapid progression to dementia, offering a focus for future studies. Identifying delirium as a potential early feature of DLB could aid in earlier recognition and improve diagnostic accuracy, particularly in individuals presenting with precipitants such as international air travel.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"471"},"PeriodicalIF":4.8,"publicationDate":"2025-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12182519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alix Joffroy (1844-1908).","authors":"Hélio Afonso Ghizoni Teive, Léo Coutinho, Francisco M Branco Germiniani, Carlos Henrique Ferreira Camargo, Olivier Walusinski","doi":"10.1007/s00415-025-13198-7","DOIUrl":"10.1007/s00415-025-13198-7","url":null,"abstract":"","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"470"},"PeriodicalIF":4.8,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144333325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of triptans use on anti-CGRP mAbs response: a prospective, cohort study.","authors":"Catello Vollono, Marina Romozzi, Antonio Munafò, Giulia Vigani, Francesco De Cesaris, Paolo Calabresi, Luigi Francesco Iannone","doi":"10.1007/s00415-025-13202-0","DOIUrl":"10.1007/s00415-025-13202-0","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to compare the differences in clinical characteristics and response to monoclonal antibodies against CGRP (anti-CGRP mAbs) between patients who habitually used triptans (TRIPTANS group) and patients who were non-current users (NO-TRIPTANS group).</p><p><strong>Methods: </strong>In this prospective cohort study, all consecutive outpatients treated with anti-CGRP mAbs for 12 months were included. Clinical data were collected at baseline and monthly: number of headache days (MHDs), the absolute number of analgesics (AMNs), and the number of days with at least one analgesic (AMDs), Headache Impact Test-6 (HIT-6), and Migraine Disability Assessment (MIDAS) questionnaires. The outcomes were to evaluate the differences between TRIPTANS and NO-TRIPTANS groups (users or non-users of triptans in the 6 months before and during anti-CGRP mAb treatment) in MHDs and the other clinical variables during treatment. Response rates were assessed based on reductions in MHDs (≤ 25%, ≥ 50%, ≥ 75%).</p><p><strong>Results: </strong>A total of 336 patients treated with mAbs were included. At baseline, NO-TRIPTANS group had higher MHDs (24.7 ± 6.7) compared to the TRIPTANS group (21.8 ± 6.9), p < 0.001. Comparative and normalized analyses showed significant and sustained lower MHDs in the TRIPTANS group during treatment. The MIDAS score was also significantly lower in the TRIPTANS group at month-3, 6, 9, 12, and lower AMDs and AMNs compared to NO-TRIPTANS group were seen in most of the time-points. The number of patients with ≥ 50% reduction of MHDs was significantly higher in the TRIPTANS group at months 1 and 12.</p><p><strong>Conclusions: </strong>This study showed greater effectiveness of anti-CGRP mAb in habitual triptans users, possibly due to a common and/or synergistic action.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"468"},"PeriodicalIF":4.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring NEK1 genetic variability in Italian amyotrophic lateral sclerosis patients.","authors":"Viviana Pensato, Silvia Peverelli, Cinzia Tiloca, Stefania Magri, Alberto Brusati, Monica Pingue, Claudia Morelli, Eleonora Dalla Bella, Arianna Manini, Pierpaola Tannorella, Alberto Doretti, Jessica Mandrioli, Fabrizia Terenghi, Alessandro Prelle, Nilo Riva, Federico Verde, Roberto Eleopra, Franco Taroni, Giuseppe Lauria Pinter, Vincenzo Silani, Nicola Ticozzi, Cinzia Gellera, Antonia Ratti","doi":"10.1007/s00415-025-13153-6","DOIUrl":"10.1007/s00415-025-13153-6","url":null,"abstract":"<p><strong>Background: </strong>Mutations in NEK1, encoding for a serine/threonine kinase which regulates several biological processes, are associated with amyotrophic lateral sclerosis (ALS).</p><p><strong>Methods: </strong>NEK1 was analysed by amplicon deep sequencing in a cohort of 1016 Italian sporadic and familial ALS patients previously screened for C9orf72, SOD1, TARDBP and FUS mutations.</p><p><strong>Results: </strong>We identified 28 rare NEK1 variants in 29 patients (2.85%) of whom 20/782 were sporadic (2.5%), 6/107 familial (5%) and 3/127 of unknown aetiology (2.3%). Variants were classified as pathogenic (P; n = 1), likely pathogenic (LP; n = 6 in 7 patients) and of unknown significance (VUS; n = 21) according the American College of Medical Genetics and Genomics criteria. Notably, 64% of the identified variants (18/28, including 4 LP and 14 VUS) were novel. Among the 29 patients with rare NEK1 variants, 7 (of whom 5 were familial cases) had additional variants in one of the four main ALS causative genes. Moreover, 23 patients carried the already reported NEK1 p.Arg261His risk variant (VUS) alone or in addition to SOD1 mutations (n = 1) or C9orf72 repeat expansion (n = 2) and to the NEK1 p.Asp128Val variant (n = 1). Genotype-phenotype correlation analysis showed no significant differences in age at onset or survival in NEK1 variant carriers, independently on the variant type. No flail arm phenotype, but atypical features, including sensory symptoms, were present in NEK1 carriers.</p><p><strong>Conclusion: </strong>Our study further expands NEK1 genetic variability by identifying novel rare variants and confirming ALS oligogenic nature since 19.6% of NEK1 patients also carried mutations in one of the four main ALS-associated genes.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"469"},"PeriodicalIF":4.8,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12179233/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of survival and prognostic factors in multiple system atrophy.","authors":"Xiao Dong, Daji Chen, Linlin Wan, Linliu Peng, Zhao Chen, Riwei Ouyang, Xiafei Long, Kefang Du, Xiaokang Wu, Xinying Xiao, Ruqing He, Rong Qiu, Beisha Tang, Hong Jiang","doi":"10.1007/s00415-025-13204-y","DOIUrl":"10.1007/s00415-025-13204-y","url":null,"abstract":"<p><strong>Background: </strong>Multiple-system atrophy is a rapidly progressive neurodegenerative disease with incomplete survival data, limiting the understanding of long-term outcomes. This study aimed to investigate a comprehensive data including survival time and prognostic factors.</p><p><strong>Methods: </strong>Individual patient data were pooled from studies reporting Kaplan-Meier curves, and then, survival curves were generated. The pooled median survival times were derived using weighted median of medians approach and hazard ratios of risk factors were analyzed using either fixed- or random-effects model.</p><p><strong>Results: </strong>37 studies involving 6145 patients were included. The median survival time for MSA patients was 8.23 years (95% CI 8.02-8.56) based on reconstructed individual patient data. The pooled weighted median time was 8.0 years (95% CI 7.51-9.0). The following variables were found as unfavorable prognostic factors (hazard ratio with 95% CI are shown): age at onset (1.02, 1.01-1.03), poor levodopa response (1.55, 1.14-2.11), parkinsonism onset (1.30, 1.05-1.62), falls (1.84, 1.4-2.4), dysautonomia onset (1.48, 1.16-1.9), autonomic failure (2.52, 1.42-4.48), orthostatism hypotension (1.39, 1.16-1.66), bladder catheterization (1.81, 1.41-2.31), and stridor (1.5, 1.12-2.02).</p><p><strong>Conclusion: </strong>Survival time in MSA was evaluated using multiple methodological approaches, revealing a median survival of 8.0 years, and clinical variables like early autonomic failure and frequently falls were identified as predictors of poor survival outcomes.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"467"},"PeriodicalIF":4.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144326078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypothalamic atrophy in CANVAS/RFC1.","authors":"Verena Miranda Souza, Camila Caroso Lobo, Thiago Junqueira Ribeiro Rezende, Gabriel Silva Schmitt, Paula Camila Alves de Assis Pereira Matos, Fabrício Diniz de Lima, Alberto Rolim Muro Martinez, Orlando Graziani Povoas Barsottini, José Luiz Pedroso, Wilson Marques, Marcondes Cavalcante França","doi":"10.1007/s00415-025-13194-x","DOIUrl":"10.1007/s00415-025-13194-x","url":null,"abstract":"<p><strong>Background: </strong>Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) is a late-onset multisystem disorder related to the RFC1 gene. Despite evidence of dysautonomia and sleep disturbances, hypothalamic involvement is unknown.</p><p><strong>Objective: </strong>We aimed to investigate hypothalamic volumetry in CANVAS/RFC1.</p><p><strong>Methods: </strong>We analyzed 19 CANVAS/RFC1 patients and 19 healthy controls using automated hypothalamic segmentation from 3 T-MRI scans. Volumetric comparisons were performed using ANCOVA, while correlations with Scale for the Assessment and Rating of Ataxia (SARA) and Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire (SCOPA-AUT) scores were assessed by Pearson's correlation.</p><p><strong>Results: </strong>CANVAS/RFC1 group had a significantly lower total hypothalamic volume (RFC1: 734.84 ± 160.49 mm³ vs Controls: 878.83 ± 136.55 mm³; P = 0.03; d = 0.99) and a reduced left tuberal superior (LTS) volume (RFC1: 71.21 ± 21.85 mm³ vs Controls: 90.30 ± 15.67 mm³; P = 0.02; d = 0.99). LTS volume inversely correlated with SARA score (R = -0.51, P = 0.049), but no associations were found with SCOPA-AUT.</p><p><strong>Conclusion: </strong>This study reveals hypothalamic atrophy in CANVAS, suggesting its role in disease pathophysiology. Further research should investigate broader hypothalamic dysfunctions and clinical implications.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 7","pages":"465"},"PeriodicalIF":4.8,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144317138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}